: TO : MTS@gnv.ifas.ufl.edu ........ Tom Sanford : murray@seattleu.edu ......... MaryAnne Murray : stever@tessi.com ............ Steve Rintala : SMIRNES@IMIHSRA.BITNET ...... S. Palazzi, MD : PHIP@TEMPLEVM.BITNET ........ Tina Phipps, Ph.D. : RRICCIUT@WCU.BITNET ......... Rae Ricciuti FROM: broedel@geomag.gly.fsu.edu .. Bob Broedel : RE : ALS CLINICAL TRIALS : As I understand it, the clinical trials will be testing products of the following companies: FOR MYOTROPHIN --- ------------------ Cephalon, Inc.; 145 Brandywine Parkway; West Chester, PA 19380. TEL 215-344-0200; FAX 215-344-0065; ATTN:Nicole Vitullo FOR CNTF --------- ------------------ Regeneron Pharmaceuticals, Inc.; 777 Old Saw Mill River Road; Tarrytown, NY 10591-6707; TEL 914-347-7000; FAX 914-347-2113 ATTN: Allison Mahlau, Secretary for Clinical Research ------------------ Synergen, Inc.; 1885 33rd Sreeet; Boulder, CO 80301-2546; TEL 303-938-6200; ATTN: Debra Unger, Administrative Coordinator for Clinical Research. ------------------ I tried to locate some informative articles about these companies and about the ALS-related clinical trials, but I could not find even one significant article about the ALS trials that we have been hearing about from the ALS Association (800-782-4747) or the MDA (800-572-1717). I was kind of wondering if the trials were really going to happen (without some kind of an info packet). I FAXed the companies for info, and they referred me to the ALS Assn and the MDA. That is, none of the three companies sent an information packet (though Regeneron did sent a list of test centers). I called some of the institutions that will be administering the trials but they could not provide an information packet either. Do any of you know details of the clinical trials? What are differences between the Regeneron and Synergen trials? Has there been any kind of a compare/contrast article explaining differences between the Myotrophin and the two CNTF tests (or between the two CNTF tests)? Or are they following some kind of an FDA guideline that we can get a copy of? Maybe we should we be contacting a person at the FDA to get an information packet? What goes? ========== The following listing is the result of a search on CompuServe's Magazine Data Base and their Health Data Base. All of these references include either "Synergen", "Regeneron", or "Cephalon" in the text of the article. But, as I was saying, I can find no good information about the ALS-related clinical trials. ========== Biotechnology public financing over $800 raised to date in 1991. (Peter Feinstein Inc.), Biotechnology public financing activities January 1-April 2, 1991. (table), AIDS Weekly, April 22, 1991 p13(2). Reference # A10686196 Text: Yes (3072 chars) Abstract: No Study shows nerve regeneration possible., Paraplegia News, April 1990 v44 n4 p12(1). Reference # A9015693 Text: Yes (1936 chars) Abstract: No Cephalon inks $20 million deal. (biotechnology company in West Chester, Pennsylvania; contract with Schering-Plough Corp.), Philadelphia Business Journal, June 4, 1990 v9 n13 p13(1). Reference # A9277509 Text: Yes (1381 chars) Abstract: No Cephalon's find may lead to Alzheimer's test. (discovers enzyme, Clipsin, that is regarded as playing a major role in the disease), Philadelphia Business Journal, March 12, 1990 v9 n1 p3(2). Reference # A8915451 Text: Yes (3253 chars) Abstract: No Brain gain: drugs that boost intelligence. (includes related articles), Omni, Sept 1992 v14 n12 p42(7). Reference # A12518322 Text: Yes (35375 chars) Abstract: Yes Dr. Parkinson's cruel disease: the search for a cure., American Health: Fitness of Body and Mind, Sept 1991 v10 n7 p54(5). Reference # A11262422 Text: Yes (7368 chars) Abstract: Yes Wall Street cranks out the shares; stock is being issued at a record-setting pace, but the tempo may be too torrid. If history is any guide, the market will cool off soon. (new common-stock offerings), U.S. News & World Report, May 20, 1991 v110 n19 p57(4). Reference # A10705272 Text: Yes (5152 chars) Abstract: No Back to a Wall Street of dreams? (brighter times on Wall Street), U.S. News & World Report, April 15, 1991 v110 n14 p16(1). Reference # A10556556 Text: Yes (1200 chars) Abstract: No Biospec. (biotechnology industry securities), The Economist, April 13, 1991 v319 n7702 p71(1). Reference # A10592787 Text: Yes (1514 chars) Abstract: No The age of investment., FW, Jan 22, 1991 v160 n2 p40(4). Reference # A9325996 Text: Yes (6867 chars) Abstract: No Decade of the brain. (neuroscience research)(includes related articles and directory of organizations representing various brain disorders) (Special Advertising Supplement), Scientific American, Sept 1992 v267 n3 pBR1(9). Reference # A12491268 Text: Yes (37758 chars) Abstract: Yes Pipeline exotica; for drugs, the more things change, the more they stay the same. (Financial World Global Report: Pharmaceuticals), Financial World, May 30, 1989 v158 n11 p72(4). Reference # A7601709 Text: Yes (9368 chars) Abstract: No Mind games. (neuropharmaceutical market may grow because of increase in understanding of the brain; includes article on difficulties of marketing diagnostic tests; Things to Come), Financial World, Nov 29, 1988 v157 n25 p42(2). Reference # A6813238 Text: Yes (4201 chars) Abstract: No Biotech. (investment opportunities in biotechnology), Omni, August 1992 v14 n11 p10(1). Reference # A12551617 Text: Yes (5025 chars) Abstract: Yes Crapshoot. (effect of changes in pharmaceutical industry on Syntex Corp.)(includes related article), FW, July 7, 1992 v161 n14 p30(3). Reference # A12377745 Text: Yes (7064 chars) Abstract: Yes A cascade of drugs: septic shock., The Economist, June 6, 1992 v323 n7762 p93(1). Reference # A12302941 Text: Yes (3708 chars) Abstract: Yes Beyond sympathy: growth factors may help heal stubborn wounds., Scientific American, Dec 1991 v265 n6 p141(1). Reference # A11637961 Text: Yes (3281 chars) Abstract: Yes Arthritis: modern treatment for that old pain in the joints. (includes articles on types of arthritis and Lyme disease), FDA Consumer, July-August 1991 v25 n6 p18(8). Reference # A11131578 Text: Yes (12937 chars) Abstract: No Mutual fund quarterly review: how first-quarter winners plan to stay on top for the rest of the year. (includes lists of 50 best and worst mutual fund performances)(Mutual Fund Watch) (column), FW, May 14, 1991 v160 n10 p58(5). Reference # A10685894 Text: Yes (4330 chars) Abstract: No Love and terror: is a chemical messenger key to treating Alzheimer's? (choline acetyltransferase, includes information on amyloid protein plaques as a cause of Alzheimer's) (Science and Business), Scientific American, April 1991 v264 n4 p148(2). Reference # A10556600 Text: Yes (4521 chars) Abstract: No Magic bullets for arthritis, diabetes .... (biotechnology innovations), American Health: Fitness of Body and Mind, July-August 1990 v9 n6 p10(1). Reference # A9076205 Text: Yes (1640 chars) Abstract: No Biotechnology: a very marketable science. (includes profile of scientists in biotechnological industries), Colorado Business Magazine, Feb 1989 v16 n2 p26(6). Reference # A7401829 Text: Yes (9897 chars) Abstract: No Biotech. (Super Stocks for Tomorrow; part 1), Changing Times, June 1987 v41 p24(8). Reference # A4832746 Text: Yes (10201 chars) Abstract: No Broad patent awarded for interleukin-1 receptor antagonist. (Synergen and University of Colorado), Cancer Weekly, Jan 6, 1992 p12(2). Reference # A11707434 Text: Yes (1147 chars) Abstract: No Company to begin three new clinical trials. (Antril, interleukin-1 receptor antagonist) (Synergen Inc.), Cancer Weekly, Dec 16, 1991 p16(1). Reference # A11656996 Text: Yes (1108 chars) Abstract: No Synergen begins clinical trials for leukemia. (trials of the drug ANTRIL for the treatment of chronic myelogenous leukemia) (Colorado), Cancer Weekly, June 24, 1991 p12(1). Reference # A10960350 Text: Yes (1406 chars) Abstract: No Additional CNTF patent. (Ciliary Neurotrophic Factor gets Patent No. 5,011,914) (Synergen Inc.), AIDS Weekly, May 6, 1991 p11(1). Reference # A10732994 Text: Yes (1337 chars) Abstract: No Ciliary Neurotrophic Factor patent awarded. (No. 4,997,929) (Synergen), AIDS Weekly, March 18, 1991 p9(1). Reference # A10581559 Text: Yes (1189 chars) Abstract: No $52.5 million raised through a partnership. (Synergen), Cancer Weekly, Feb 25, 1991 p11(1). Reference # A10424625 Text: Yes (1386 chars) Abstract: No IL-1RA reduces proliferation of leukemia cells. (interleukin-1 receptor antagonist) (Synergen), NCI Cancer Weekly, Dec 17, 1990 p10(1). Reference # A9246822 Text: Yes (1174 chars) Abstract: No New product director and assistant director of clinical research appointed. (Pal Hastings and John Pribble) (Synergen), CDC AIDS Weekly, Oct 1, 1990 p16(1). Reference # A8980258 Text: Yes (1672 chars) Abstract: No New protein could protect against AIDS drug side effects. (Synergen Inc.; protein called CNTF), CDC AIDS Weekly, Dec 25, 1989 p4(1). Reference # A8238193 Text: Yes (1584 chars) Abstract: No == end of als 2 ==